On May 8, ABIOMED, Inc. (NASDAQ:ABMD) posted earnings per share of 9 cents for the fourth quarter of its fiscal 2014, which was flat compared with the year-ago earnings as well as the Zacks Consensus Estimate. However, net earnings fell 3.2% to $3.6 million from $3.7 million in the fiscal 2013-fourth quarter. ABIOMED, Inc. (NASDAQ:ABMD) net profit margin is 4.00%and weekly performance is -0.42%. On last trading day company shares ended up $21.50. Analysts mean target price for the company is $89789. ABIOMED, Inc. (NASDAQ:ABMD) distance from 50-day simple moving average (SMA50) is -13.91%.
Abbott Laboratories (NYSE:ABT) said Friday it agreed to buy CFR Pharmaceuticals for $2.9 billion to expand its business in the fast-growing Latin American markets. Abbott will acquire the holding company that indirectly owns about 73% of Santiago, Chile-based CFR and will conduct a public cash offer for all outstanding shares of CFR. Abbott will also assume CFR’s debt of about $430 million. Abbott Laboratories (NYSE:ABT) shares fell -0.46% in last trading session and ended the day on $39.06. ABT Gross Margin is 54.00% and its return on assets is 6.90%. Abbott Laboratories (NYSE:ABT) quarterly performance is 1.24%.
On May 16, Natus Medical Inc (NASDAQ:BABY) management meet with Roth Capital, hosted by Roth Capital. Natus Medical Inc (NASDAQ:BABY) shares moved down -0.20% in last trading session and was closed at $24.44, while trading in range of $23.69 – $24.56. Natus Medical Inc (NASDAQ:BABY) year to date (YTD) performance is 8.62%.
Zacks restated their neutral rating on shares of CONMED Corporation (NASDAQ:CNMD) in a research note issued to investors on Friday, Stock Ratings News reports. The firm currently has a $47.00 price target on the stock. CONMED Corporation (NASDAQ:CNMD) ended the last trading day at $49.61. Company weekly volatility is calculated as 2.92% and price to cash ratio as 23.99. CONMED Corporation (NASDAQ:CNMD) showed a positive weekly performance of 3.16%.